Shots:

• Boehringer Ingelheim has acquired Global Stem cell Technology (GST) focusing to strengthen its portfolio capabilities to accelerate innovation and growth
• The acquisition follows two years of partnership b/w the companies that brought the first-ever registered stem cell-based veterinary medicine (Arti-Cell Forte) in the EU
• The acquisition of GST will accelerate the development pipeline of Boehringer Ingelheim while maintaining its focus on setting new standards of care for animals. Arti-Cell Forte is testimony to the innovation strength that lies within both companies

­ Ref: Boehringer Ingelheim | Image: GST